AChE drugs mainly dopenzil, rivastigmine and galanthamine hydrobromide approved by FDA [8] for treatment of AD which improves perception by elevating neurotransmission of ACh at cholinergic synapse through catabolic inhibition of acetylcholine into acetate and choline [9]. Here, ACHE is linked to Alzheimer disease.